Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 16:34 ET | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
January 08, 2026 16:05 ET | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
January 07, 2026 08:01 ET | Source: Vaxxas Pty Ltd

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive...
December 22, 2025 02:17 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag SVF Vaccines planerar notering på Nasdaq First North Premier genom ett omvänt förvärv inför accelererad vaccinutveckling

STOCKHOLM, 22 december 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines AB har ingått en icke-bindande avsiktsförklaring med Novakand Pharma AB...
December 22, 2025 02:17 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development

STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand...
December 14, 2025 08:01 ET | Source: Vaxxas Pty Ltd

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration...
November 26, 2025 07:13 ET | Source: Research and Markets

Infectious Vaccine Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 543 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Infectious Vaccine Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a...
November 26, 2025 07:04 ET | Source: Research and Markets

Vaccine Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 818 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Vaccine Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing...
November 17, 2025 08:00 ET | Source: SNS Insider pvt ltd

Protein Therapeutics Market Set to Hit USD 645.61 Billion by 2032 as Biologics, Precision Medicine, and Advanced Biotechnology Accelerate Global Adoption – SNS Insider

Austin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protein Therapeutics Market Size & Trends: According to SNS Insider, The Protein Therapeutics Market size was valued at USD 375.32 billion in 2024 and...
November 10, 2025 08:00 ET | Source: Vaxxas Pty Ltd

Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards Market

Australian needle-free vaccine patch company Vaxxas appoints global pharmaceutical executive to Board as it accelerates product to market.